ArticleBMJ open2025

Is first-line treatment with polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model.

Liangliang Dong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.